The Centers for Medicare & Medicaid Services (CMS) has finalized comprehensive changes to Medicare reimbursement for skin substitute products used in wound care. Effective January 1, 2026, the rule restructures Medicare Part B payment methodology across hospital outpatient and non-facility settings, shifting away from the traditional average sales price (ASP) model toward a standardized flat-rate payment [1].
This represents one of the most significant wound care reimbursement reforms in recent years, with important implications for providers, manufacturers, and organizations operating in value-based care environments.
Why CMS Acted
Medicare spending on skin substitutes has grown dramatically. In 2019, Part B spending for these products was roughly $250 million, but by 2024 it had soared to more than $10 billion, outpacing utilization increases and prompting concerns about pricing variability and program integrity [2].
Federal watchdogs, including the HHS Office of Inspector General (OIG), have raised alarms about questionable billing patterns, inconsistent ASP reporting, and vulnerabilities to fraud, waste, and abuse under the existing reimbursement model [2].
In response, CMS finalized a new payment framework on November 5, 2025 that is designed to promote standardized reimbursement and more predictable spending [1].
Key Policy Changes
Transition to a Flat-Rate Payment Model
Under the new rule, most skin substitute products previously reimbursed under the ASP methodology will transition to a standardized flat rate of $127.28/cm2. Certain biologics regulated under Section 351 of the Public Health Service Act will remain reimbursed under ASP. However, the majority of products will fall under the flat-rate model [1].
By reducing payment variability across similar products, CMS aims to better align reimbursement with clinical appropriateness and utilization, rather than product price alone [1].
Continued Oversight and Documentation Requirements
CMS paired the new payment model with continued oversight to ensure appropriate utilization and accurate coding. Providers must maintain strong documentation of medical necessity and clinical rationale to support claims and withstand audits [1].
Operational Implications for Providers and Manufacturers
For physician practices and wound care clinics, reimbursement will no longer scale with product acquisition cost. As a result, organizations will need to reassess product selection, utilization patterns, documentation practices, and revenue cycle workflows. Clinical appropriateness and medical necessity will be central to financial sustainability.
Manufacturers will likewise need to adapt. With reimbursement less dependent on list price, differentiation will increasingly rely on demonstrated clinical outcomes, real world evidence, and cost effectiveness within defined patient populations. Education and documentation support will become even more important in a heightened compliance environment [1].
Alignment With Value Based Care and ACOs
Although the rule requires operational recalibration, it more closely aligns skin substitute reimbursement with core value-based care principles. By replacing the ASP driven methodology with a standardized flat rate, CMS reduces incentives tied to product price escalation and instead centers reimbursement on clinical appropriateness, efficiency, and measurable outcomes.
Under the prior model, payment variability could create financial distortion between clinically comparable products. The flat rate structure shifts the focus away from acquisition cost and toward disciplined utilization, documentation integrity, and evidence-based decision making. These are foundational elements of accountable care.
For Accountable Care Organizations, including those supported by Advanced Management USA, this transition reinforces structural advantages inherent in coordinated, data driven systems of care:
- Advanced utilization analytics to monitor application frequency, wound progression, and cost per episode of care
- Evidence based clinical pathways that reduce unwarranted variation and support consistent medical necessity documentation
- Integrated compliance infrastructure designed to withstand increased scrutiny from CMS and federal oversight agencies
- Population health strategies focused on early wound identification, chronic disease management, and total cost of care optimization
The predictability introduced by a standardized rate strengthens financial modeling within shared savings arrangements. Reduced reimbursement volatility allows ACOs to more accurately forecast episode costs, align physician incentives, and manage specialty utilization within broader population health strategies.
In this environment, success will favor organizations that combine clinical discipline, strong data governance, and proactive compliance oversight, capabilities that are central to the Advanced Management USA operating model.
Positioning for Success Under the 2026 Rule
To succeed under the flat-rate model, providers and partners should prioritize:
- Ongoing training for clinical and billing teams
- Monitoring financial performance under the new methodology
- Internal audits to validate medical necessity and coding accuracy
- Strategic review of product mix and vendor relationships
For Advanced Management USA and its ACO partners, these reforms reinforce the importance of strong infrastructure. Our focus on compliance, data transparency, and provider enablement ensures that policy shifts such as this are operationalized strategically rather than reactively.
Looking Ahead
CMS’s final rule on skin substitute payment reform reflects a broader shift toward consistent, cost-conscious Medicare reimbursement that supports sustainability and value-based care goals. Although operational adjustments are required, the reforms reinforce the central principles of value-based care: appropriate utilization, accountability, and improved patient outcomes.
For ACOs operating under shared savings models, the new framework better aligns with clinical excellence with financial stewardship. Advanced Management USA remains committed to equipping provider partners with the analytics, compliance oversight, and population health tools necessary to thrive in this evolving regulatory landscape.
References
[1] Polsinelli. CMS Finalizes Sweeping Reforms to Skin Substitute Payments Amid Rising Costs and Enforcement Activity. November 10, 2025.
https://www.polsinelli.com/publications/cms-finalizes-reforms-skin-substitute-payments-rising-costs-enforcement-activity
[2] U.S. Department of Health and Human Services Office of Inspector General. Medicare Part B Payment Trends for Skin Substitutes Raise Major Concerns About Fraud, Waste, and Abuse, OEI-BL-24-00420. Issued 09/03/2025; posted 09/08/2025.
https://oig.hhs.gov/reports/all/2025/medicare-part-b-payment-trends-for-skin-substitutes-raise-major-concerns-about-fraud-waste-and-abuse/
